p16、p53、BRAF、Bcl-2在卵巢浆液性肿瘤组织中的表达及临床意义  

Expression and clinical significance of p16,p53,BRAF and Bcl-2 in serous ovarian neoplasm tissue

作　　者：田海萍[1] 马莉琼[1] 黑静雅[1] 孙金萍[1] 朱萌 Tian Haiping;Ma Liqiong;Hei Jingya;Sun Jinping;Zhu Meng(Department of Pathology,General Hospital of Ningxia Medical University,Ningxia Yinchuan 750004,China;Basic Medical College,Ningxia Medical University,Ningxia Yinchuan 750004,China.)

机构地区：[1]宁夏医科大学总医院病理科,宁夏银川750004 [2]宁夏医科大学基础医学院,宁夏银川750004

出　　处：《现代肿瘤医学》2020年第16期2865-2870,共6页Journal of Modern Oncology

基　　金：宁夏医科大学临床医学院2017年度学位点建设导师孵育科研项目。

摘　　要：目的:探讨卵巢浆液性肿瘤组织中p16、p53、BRAF、Bcl-2的表达及临床意义。方法:收集宁夏医科大学总医院病理科2017年至2018年确诊的卵巢浆液性肿瘤136例,其中浆液性囊腺瘤52例,交界性囊腺瘤22例,低级别浆液性癌18例,高级别浆液性癌44例;另收集卵巢良性肿瘤和卵巢癌手术切除标本各30例。分别采用免疫组织化学SP法检测p16、p53、BRAF、Bcl-2的表达,实时定量PCR法检测p16、p53在卵巢良恶性肿瘤组织中的表达。结果:卵巢浆液性囊腺瘤、交界性囊腺瘤、低/高级别浆液性癌组织中p16的阳性率分别为3.8%、45.5%、88.9%、81.8%,p53为0、9.1%、 55.6%、45.5%,BRAF为46.2%、45.5%、 22.2%、31.8%,Bcl-2为46.2%、45.5%、38.9%、47.7%。不同类型浆液性肿瘤组织中p16、p53表达均有显著性差异(P<0.001),但BRAF、Bcl-2表达未见明显差异。与卵巢良性肿瘤相比,p16在交界性肿瘤、卵巢癌中的阳性表达明显升高,差异有显著统计学意义(P<0.012 5);p53在卵巢癌中的阳性表达明显高于良性肿瘤(P<0.001);p16和p53的表达呈正相关(P<0.05)。p53、Bcl-2与卵巢癌淋巴结转移有相关性(P<0.001),p16、p53、Bcl-2与盆腔侵犯有关(P<0.05),p53、BRAF、 Bcl-2与CA125表达有不同程度相关性(P<0.05)。p16、p53联合检测对卵巢癌诊断的敏感性和特异性为90.0%、76.7%。结论:p16、p53、BRAF、Bcl-2参与卵巢癌的发生发展,p16和p53基因突变可能在卵巢浆液性肿瘤的恶性进展中发挥作用,联合检测p16、p53对卵巢癌诊断有指示意义。Objective:To investigate the expression and clinical significance of p16,p53,BRAF and Bcl-2 in serous ovarian neoplasm.Methods:136 specimens of serous ovarian neoplasm were collected from the Department of Pathology,General Hospital of Ningxia Medical University from 2017 to 2018,including 52 serous cystadenomas,22 borderline serous cystadenomas,18 low-grade serous carcinomas and 44 high-grade serous carcinomas.Another 30 cases of benign ovarian tumors and 30 cases of surgical resection of ovarian cancer were also collected.The expressions of p16,p53,BRAF and Bcl-2 were detected by immunohistochemical SP method,and the expression of p16,p53 in benign and malignant ovarian tumors were detected by real-time PCR,respectively.Results:The positive rates of p16 in ovarian serous cystadenoma,borderline cystadenoma,low-grade serous carcinoma and high-grade serous carcinoma were 3.8%,45.5%,88.9%,81.8%,and 0,9.1%,55.6%,45.5%for p53,and 46.2%,45.5%,22.2%,31.8%for BRAE and 46.2%,45.5%,38.9%,47.7%for Bcl-2,respectively.There were significant differences for the expression of p16 and p53 in different serous tumors(P<0.001),but there was no significant difference for the expression of BRAF and Bcl-2.Compared with benign ovarian tumors,the positive expression of p16 in borderline tumors and ovarian cancer was significantly higher(P<0.0125).The positive expression of p53 in ovarian cancer was significantly higher than that in benign tumors(P<0.001).There were positive correlation between p16 and p53(P<0.05).p53 and Bcl-2 were correlated with lymph node metastasis of ovarian cancer(P<0.001).p16,p53 and Bcl-2 were associated with pelvic invasion(P<0.05),and p53,BRAF and Bcl-2 were correlated with CA125 expression(P<0.05).The sensitivity and specificity of p16 and p53 in the diagnosis of ovarian cancer were 90.0%and 76.7%.Conclusion:p16,p53,BRAF and Bcl-2 are involved in the occurrence and development of ovarian cancer.The mutations of p16 and p53 genes may play an important role in the malignant progression of serous ovarian neopla

关 键 词：卵巢浆液性肿瘤 P16 p53 BRAF BCL-2 免疫组织化学 

分 类 号：R737.31[医药卫生—肿瘤]